Presentation is loading. Please wait.

Presentation is loading. Please wait.

CAR8 failure in an OT1 TCR transgenic T cell after exposure to OVA

Published byCecily Bryant Modified over 5 years ago

Similar presentations

Presentation on theme: "CAR8 failure in an OT1 TCR transgenic T cell after exposure to OVA"— Presentation transcript:

1 Fig. 5. CAR8 failure in an OT1 TCR transgenic T cell after exposure to OVA.
CAR8 failure in an OT1 TCR transgenic T cell after exposure to OVA. (A) CD107a expression on OT1-CAR T cells generated from Rag1−/− OT1 spleens at 4 hours of coincubation with E2aPbx expressing CD19 and/or OVA antigens. Iso cntrl, isotype control. (B) Percent viable E2aPbx cells expressing varying combinations of the CD19 and OVA antigens after 3 days of coculture with OT1-CAR or mock-OT1 T cells. (C) OVA-expressing hematopoietic chimeras were generated by CD3-depleted bone marrow transplant 21 days before inoculation with 1 × 106 E2aPbx, with lymphodepletion and 1 × 106 CD19 OT1-CAR8 cell treatment on day 0. (D) Survival of OVA chimeric mice treated with OT1-CAR8 T cells. (E) Leukemia burden of OT1-CAR8–treated mice 7 days after infusion. BM, bone marrow. (F and G) Analysis of infused OT1-CAR8 cells from the bone marrow 7 days after infusion. (F) PD-1 expression and (G) LAG3 expression on OT1-CAR8 cell [for (E) to (G): *P < 0.05, **P < 0.01, ***P < 0.001, ****P < , relative to the WT→WT group, one-way ANOVA performed for all comparisons and log-rank Mantel-Cox test for survival analysis]. Yinmeng Yang et al., Sci Transl Med 2017;9:eaag1209 Published by AAAS

Download ppt "CAR8 failure in an OT1 TCR transgenic T cell after exposure to OVA"

Similar presentations

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia by Michael Kalos, Bruce.

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia by Michael Kalos, Bruce.
Fig. 1. TP is highly expressed in myeloma.

Fig. 1. TP is highly expressed in myeloma.
Fig. 6. Transgenic expression of αLNNd and mag in dyW/dyW mice improves muscle function, increases body weight, and prolongs life span. Transgenic expression.

Fig. 6. Transgenic expression of αLNNd and mag in dyW/dyW mice improves muscle function, increases body weight, and prolongs life span. Transgenic expression.
Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.

Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.
Transfer of miR-223 during neutrophil-epithelial cell interactions

Transfer of miR-223 during neutrophil-epithelial cell interactions
Fig. 2. Mechanism of PD-L1 down-regulation in NOD HSPCs.

Fig. 2. Mechanism of PD-L1 down-regulation in NOD HSPCs.
Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to.

Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to.
Fig. 1 Increasing UCB cell dose impairs short-term progenitor cell engraftment. Increasing UCB cell dose impairs short-term progenitor cell engraftment.

Fig. 1 Increasing UCB cell dose impairs short-term progenitor cell engraftment. Increasing UCB cell dose impairs short-term progenitor cell engraftment.
In vivo responses of AMLMLL to ATRi.

In vivo responses of AMLMLL to ATRi.
Fig. 4. Biomechanical properties of treated tibiae.

Fig. 4. Biomechanical properties of treated tibiae.
Fig. 8. In vivo suppression of MM by CMLD

Fig. 8. In vivo suppression of MM by CMLD
Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.
Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.
Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.
Fig. 4 Topical application of SAAP-148 ointment eradicates acute and established infections of MRSA and A. baumannii from the skin. Topical application.

Fig. 4 Topical application of SAAP-148 ointment eradicates acute and established infections of MRSA and A. baumannii from the skin. Topical application.
Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade

Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade
Fig. 1 ZIKV-related flaviviruses cause fetal demise in mice that can be prevented by mAb treatment. ZIKV-related flaviviruses cause fetal demise in mice.

Fig. 1 ZIKV-related flaviviruses cause fetal demise in mice that can be prevented by mAb treatment. ZIKV-related flaviviruses cause fetal demise in mice.
Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.
Fig. 4. The effects of AVP or d(Leu4Lys8)VP, a specific AVPR1B agonist, on anemic rodents. The effects of AVP or d(Leu4Lys8)VP, a specific AVPR1B agonist,

Fig. 4. The effects of AVP or d(Leu4Lys8)VP, a specific AVPR1B agonist, on anemic rodents. The effects of AVP or d(Leu4Lys8)VP, a specific AVPR1B agonist,
Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival by Matthew Gumbleton, Raki Sudan,

Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival by Matthew Gumbleton, Raki Sudan,

Similar presentations

Ads by Google